Stockscreener 앱 받기
10.44
3.16%
0.32
시간 외 거래:
9.97
-0.47
-4.50%
전일 마감가:
$10.12
열려 있는:
$11.13
하루 거래량:
6,877
Relative Volume:
1.15
시가총액:
$99.48M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+3.06%
1개월 성능:
-38.26%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$9.8625
$11.13
1주일 범위
$9.81
$11.16
52주 변동 폭
$9.75
$22.63
Exozymes Inc Stock (EXOZ) Company Profile
명칭
Exozymes Inc
전화
(626) - 415 - 1488
주소
750 ROYAL OAKS DR, MONROVIA
EXOZ을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EXOZ
Exozymes Inc
|
10.44 | 99.48M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 66.76B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Exozymes Inc 주식(EXOZ)의 최신 뉴스
eXoZymes Inc. Reports 2024 Progress and IPO Success - TipRanks
eXoZymes Provides Fourth Quarter and Full Year 2024 Update - GlobeNewswire
eXoZymes appoints new chief commercial officer By Investing.com - Investing.com Canada
eXoZymes appoints new chief commercial officer - Investing.com
eXoZymes appoints experienced biomanufacturing executive, Damien Perriman, as CCO - GlobeNewswire
Strategic Win: eXoZymes Taps 20-Year Biotech Leader to Drive Commercial Growth - Stock Titan
eXoZymes Unveils AI-Powered Enzyme Breakthrough in First Earnings Since Nasdaq Debut - Stock Titan
MDB Capital's Remarkable Growth: AUM Soars 2100%, New Platform Launch Drives Expansion - Stock Titan
New to The Street Show #639 Premieres Nationwide on Bloomberg Television, March 29 at 6:30 PM EST Featuring BioVie, Roadzen, Tonix Pharma, and eXoZymes Inc. - ACCESS Newswire
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
eXoZymes to Host Fourth Quarter and Full Year 2024 Results Conference Call on Wednesday April 2, 2025 - GlobeNewswire
AI Enzyme Pioneer EXOZ Reveals 2024 Financial Performance: Q4 Earnings Call Details - Stock Titan
New to The Street’s FOX Business Show #638 Spotlights Visionary CEOs and Breakthrough Innovations Across Health, AI, and Insurance Featuring BioVie CEO Cuong Do, Roadzen CEO Rohan Malhotra, Lou Basenese’s The Big Skinny on eXoZymes, and B - The State
New to The Street's FOX Business Show #638 Spotlights Visionary CEOs and Breakthrough Innovations Across Health, AI, and Insurance Featuring BioVie CEO Cuong Do, Roadzen CEO Rohan Malhotra, Lou Basenese's The Big Skinny on eXoZymes, and B - ACCESS Newswire
MDB Capital's 2024 Financial Results: CEO to Reveal Full Year Performance and Strategic Outlook - StockTitan
Who's Winning the AI Data Center Patent Race? New Report Reveals Surprising Leader - StockTitan
New to the Street Airs Show #630 on Fox Business Network Tonight at 10:30 PM PST Featuring Roadzen ($RDZN), BioVie ($BIVI), AtlasClear (ATCH), eXoZymes ($EXOZ), and EvolveHealthandLifestyle. - Markets Insider
New to the Street Airs Show #630 on Fox Business Network Tonight at 10:30 PM PST Featuring Roadzen ($RDZN), BioVie ($BIVI), AtlasClear (ATCH), eXoZymes ($EXOZ), and EvolveHealthandLifestyle.com With Craig Bruce - Corsicana Daily Sun
New to the Street Airs Show #630 on Fox Business Network Tonight at 10:30 PM PST Featuring Roadzen ($RDZN), BioVie ($BIVI), AtlasClear (ATCH), eXoZymes ($EXOZ), and EvolveHealthandLifestyle.com With C - StreetInsider
eXoZymes president, chairman Hayat transitions out of roles - MSN
EXoZymes, Inc. Announces Management Changes -February 21, 2025 at 04:37 pm EST - Marketscreener.com
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
ExoZymes Inc. appoints new board member and chairman By Investing.com - Investing.com Nigeria
eXoZymes Announces Leadership Changes with New Appointments - TipRanks
eXoZymes and MDB Capital Announce Leadership Transition at - GlobeNewswire
ExoZymes Inc. appoints new board member and chairman - Investing.com
eXoZymes Inc. Announces Leadership Changes and Rebranding Following Transition from Invizyne Technologies - Nasdaq
eXoZymes and MDB Capital Announce Leadership Transition at eXoZymes Inc. - GlobeNewswire
Exozymes (EXOZ) Income Statement & Balance Sheet 2025 - MarketBeat
eXoZymes Inc Rings the Nasdaq Stock Market Closing Bell - Nasdaq
eXoZymes Inc Rings the Closing Bell - Nasdaq
Reynolds Consumer Products, Inc Rings the Nasdaq Stock Market Opening Bell - Nasdaq
Biotech’s New Frontier: Discover the “Exozymes Era” Revolutionizing Chemical Production - Mi Valle
The Dawn of an Era: eXoZymes Ushers in a New Age of Biotechnology - Jomfruland.net
eXoZymes Announces Nasdaq Bell Ringing to Commemorate Initial Public Offering - GlobeNewswire
Can This AI-Powered Enzyme Company Transform the Future of Biotech? Nasdaq's Newest IPO Makes Bold Claims - StockTitan
Decibel Expands General Admission Brand's International Footprint - The Globe and Mail
Triller Group Inc Rings the Nasdaq Stock Market Opening Bell - Nasdaq
3 Travel Stocks That Show the Travel Boom Is Far from Over - The Globe and Mail
Semtech Shares Plummet on AI Server Woes—Is a Turnaround Ahead? - The Globe and Mail
Analysts See Buying Opportunity in NVIDIA Before Earnings - The Globe and Mail
Prediction: ASML Will Beat the Market. Here's Why. - The Globe and Mail
3 Consumer Staples ETFs for Stability in a Volatile Market - The Globe and Mail
GCL Global Holdings Ltd. Rings the Nasdaq Stock Market Closing Bell - Nasdaq
Positive week for Invizyne Technologies, Inc. (NASDAQ:EXOZ) institutional investors who control 42% of the company - Simply Wall St
Invizyne Technologies, Inc. will Change its Name to eXoZymes, Inc -February 12, 2025 at 12:00 am EST - Marketscreener.com
Invizyne Technologies, Inc. will Change its Ticker to EXOZ from IZTC -February 12, 2025 at 12:00 am EST - Marketscreener.com
Should You Forget AMD and Buy 2 Tech Stocks Instead? - The Globe and Mail
What’s in a Name: Out with Invizyne, In with eXoZymes - Genetic Engineering & Biotechnology News
Rebranding Invizyne to eXoZymes Signifies a Sustainable - GlobeNewswire
Invizyne Technologies rebrands as eXoZymes with new ticker EXOZ - MSN
Exozymes Inc (EXOZ) 재무 분석
Exozymes Inc (EXOZ)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
1.23%
1.63%
자본화:
|
볼륨(24시간):